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ABSTRACT  
Inhibition of aromatase (CYTP450) as a key enzyme in the estrogen biosynthesis could result 
in regression of estrogen-dependent tumors and even preventing the promotion of breast can-
cer. Although today potent steroid and non-steroid inhibitors of aromatase are available, iso-
flavanone derivatives as natural compounds with least side effects have been described as the 
candidate for a new generation of aromatase inhibitors. 2a as an isoflavanone derivative is the 
most potent inhibitor of aromatase, synthesized by Bonfield et al. (2012). In our computation-
al study, the mentioned compound was used as the template for virtual screening. Between 
286 selected compounds with 70 % of structural similarity to 2a, 150 of them showed lower 
docking energy in comparison with 2a. Compound 2a_1 with 11.2 kcal/mol had the lowest 
docking energy. Interaction of 2a_1 with aromatase was further investigated and compared 
with 2a and androstenedione (ASD) as a natural substrate of aromatase, through 20 ns of mo-
lecular dynamic simulation. Analysis of trajectories showed, while ASD interacts with aroma-
tase through hydrogen bonds and 2a just interacts via hydrophobic forces, 2a_1 not only ac-
commodates in the hydrophobic active site of aromatase in a suitable manner but it also 
makes a stable coordination with iron atom of aromatase heme group via OB. 
 
Keywords: Aromatase, androstenedione, aromatase inhibitor, structural-based virtual screen-
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INTRODUCTION  
Breast cancer is the first widespread 
kind of cancer among women and after lung 
cancer is the major cause of death due to 
malignancy (Hernandez et al., 2010). Es-
trogens, through various mechanisms, have 
the predominant role in induction and pro-
liferation of breast cancers (Santen and 
Harvey, 1999). Estrogens could cause car-
cinogenesis synergically through accelerat-
ing cell division, which results in abridging 
the time of DNA repairing phase, and as 
additive fashion, with creation of quinines 
via their metabolic pathway (Santen et al., 
1999). Breast cancer tumors can be catego-
rized as hormone-depended or independent 
of hormone stimulation subtypes (Santen 
and Harvey, 1999). In hormone-dependent 
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case of breast cancer, estrogen plays a cru-
cial role in development of tumors through 
binding to estrogen receptors, which leads 
to induction of intracellular signaling cas-
cades (Berstein et al., 1999; Buzdar, 1999). 
Estrogen-dependent carcinomas were re-
ported in near 60 percent of premenopausal 
and 75 percent of post-menopausal breast 
cancer patients (Chen, 1998). So, inhibition 
of aromatase as the rate limiting enzyme in 
the estrogen biosynthesis pathway could 
limit the growth and development of estro-
gen-dependent tumors. In addition, such 
inhibition might cause an attenuation of es-
tradiol level in breast tissue, which finally 
results in prevention of the tumor promo-
tion process (Santen et al., 1999). 
Aromatase, also known as Cytochrome 
P450, is a key enzyme which converts cho-
lesterol to estradiol E2 as the most biologi-
cally active estrogen (Simpson et al., 1994). 
Aromatase contains a catalytic heme group 
with an iron atom forming an octahedral 
coordination geometry which is responsible 
for oxidation of substrate (Favia et al., 
2006). The iron atom in heme group of 
aromatase is coordinated by four nitrogen 
atoms of protoporphyrin IX and a thiolate 
group from Cys437. Its sixth coordination 
is occupied by water molecule which is 
necessary for hydroxylation process 
(Auclair et al., 2001; Meunier et al., 2004). 
In the presence of three moles of oxygen 
and three moles of NADPH, aromatase cat-
alyzes the transformation of one mole of 
androstenedione (ASD) to estrone E1 
through a three-step reaction which is the 
rate limiting step in the synthesis of estradi-
ol E2 (Meunier et al., 2004). Synthesis of 
19-hydroxyandrostenedione from ASD 
through hydroxylation of C19, production 
of 19-gem-dihydroxyandrostenedione via 
another hydroxylation on C19 and genera-
tion of estrone E1 which accompany with 
extrication of a water molecule and produc-
tion of a formate molecule, are the three 
steps of an aromatization process which is 
mediated by aromatase (Meunier et al., 
2004). Moreover, aromatase has a crucial 
role in metabolisms of xenobiotics, drugs 
and other kinds of steroids (Guengerich, 
2004; Williams et al., 2000).  
Aminoglutethimide and testololactone 
are the first-generation inhibitors of aroma-
tase which result in regression of tumors in 
administrated patients. They don't act as 
potent kinds of inhibitors and their unspe-
cific action leads to induction of side-
effects (Santen et al., 1990). Today, FDA-
approved drugs such as exemestane 
(Coombes et al., 2004) as an steroid inhibi-
tor, letrozole (Coates et al., 2007) and anas-
trozole (Locker et al., 2007) as non-steroid 
specific aromatase inhibitors (AIs) can effi-
ciently decrease the recurrence rate of hor-
mone-dependent breast cancer. Exemestane 
is a mechanism-based inhibitor and inhibits 
aromatase in an irreversible manner (Hong 
et al., 2007) but other AIs like letrozole and 
anastrozole act in a competitive and re-
versible inhibition procedure, so their 
mechanism of action still remains unclear 
(Hong et al., 2011; Kao et al., 1996).  
Although today, non-steroid aromatase 
inhibitors (NSAIs) are the most progressive 
kinds (Bhatnagar, 2007), the occurrence 
probability of side-effects due to long-term 
administration has motivated new attempts 
for development of a new generation of AIs 
based on natural compounds and their de-
rivatives such as coumarin, lignin and fla-
vonoids (Sakamoto et al., 2010). Structural 
modification of isoflavanone through vari-
ous approaches by Bonfield et al. (2012) 
resulted in production of new derivatives 
with greater ability for inhibition of aroma-
tase activity. Among synthesized deriva-
tives, the compound named 2a (Figure 2B) 
with IC50 of 0.26 µM was the most efficient 
inhibitor of aromatase (Bonfield et al., 
2012). In the present study, inhibitory 
mechanism of compound 2a was further 
investigated and its interaction with aroma-
tase in the presence of its natural substrate, 
ASD, was studied through 20 ns of molecu-
lar dynamic simulation (MD simulation). 
Furthermore, structure-based virtual screen-
ing method was applied to develop new 
compounds with more potent inhibitory ef-
fect.  
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MATERIALS AND METHODS  
Ligand-based virtual screening  
The ZINC database (Irwin et al., 2012), 
a free virtual screening database containing 
over 21 million compounds in ready-to-
dock 3D formats, was investigated for 
structures with 70 % similarity to 2a 
(http://zinc.docking.org/). 286 purchasable 
compounds with 70 % of structural simi-
larity to 2a were captured in this way and 
used for structure-based virtual screening.  
 
Biological activity 
The negative logarithm of the measured 
IC50 (M) against human aromatase (pIC50) 
(Bonfield et al., 2012) was used in Pearson 
correlation.  
 
Structure-based virtual screening  
All of the 286 captured compounds 
were docked against the crystal structure of 
aromatase (PDB code: 3S79) obtained from 
protein databank (Berman et al., 2000). Ac-
quired file contains aromatase with its natu-
ral substrate, ASD, in 2.75 Å resolution. 
AutoDock Vina was used as docking tool 
(Trott and Olson, 2010) and AUDocker LE 
was applied for automatic consequential 
docking process (Sandeep et al., 2011). All 
of default settings were assigned during the 
docking procedure. Usually, docking pro-
grams use a scoring function to approxi-
mate the standard chemical potentials of the 
defined complex system. Scoring function 
of AutoDock Vina is defined as below 
(Trott and Olson, 2010): 
ΔGbinding = ΔGgauss + ΔGrepulsion + ΔGhbond + 
ΔGhydrophobic + ΔGtors (1) 
The scoring function mentioned above 
was calibrated with approximately 1300 
receptor-ligand complexes. Furthermore, its 
algorithm search is gradient-based local 
search (Chang et al., 2010). The confor-
mation-dependent part of the scoring func-
tion AutoDock Vina could be shown as 
equation 2: 
c =  Ʃi<j ftitj(rij) (2) 
which ftitj is the interaction function of 
two atoms i and j. rij is the distance between 
atoms i and j (Trott and Olson, 2010). Val-
ue c is calculated for both intra and inter-
molecular bonds:  
c = cinter + cintra (3) 
In order to linking between windows 
system and AutoDock Vina in our virtual 
screening study, AUDocker LE software 
was used. By the aid of this software, the 
ligand efficiency could also be calculated. 
By dividing the theoretical ΔGbinding value 
by the number of non-hydrogen atoms, the 
ligand efficiency value is achieved (Abad-
Zapatero and Metz, 2005; Hopkins et al., 
2004): 
LEligand =  ΔG/N (4) 
where ΔG is proportional to Kd  :  
ΔG = RTLnKd  (5) 
and N is the number of non-hydrogen 
atoms. 
 
Molecular simulation of aromatase and 
aromatase-ligand complexes  
Interaction of ASD, 2a and 2a_1 which 
had the lower docking energy between all 
of the docked compounds were more inves-
tigated through 20 ns of MD simulation. 
With regard to this note that the structure of 
protein determined by X-ray crystallo-
graphy is lacked of hydrogen, at the first 
step, missing hydrogen atoms were added 
to aromatase PDB file. The crystal structure 
of aromatase was prepared for MD simula-
tion through mild minimization, and then 
solvation within a cubic shaped water cage 
with 1 Å of distance between protein pe-
riphery and the cube edges. System neutral-
ization was applied by addition of three 
chloride ions and then, another energy min-
imization step was implemented. All MD 
simulations were carried out by the 
GROMACS 4.5.5 package using the ffgmx 
force field (Gromos87) (van der Spoel et 
al., 2005). Before the production MD simu-
lation run, the temperature of crystal struc-
ture was reached to 300 K and equilibrated 
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during 50 ps in NVT ensemble. After an-
other equilibration step which performed 
through 100 ps of NPT simulation, the crys-
tal structure of aromatase was simulated 
through 20 ns of NPT ensemble. Molecular 
dynamic simulations of aromatase alone 
and in the presence of ASD, 2a and 2a_1 
were individually done as mentioned above. 
Topologies and coordinations of ligands 
were generated by PRODRG web server 
(Schuttelkopf and van Aalten, 2004). For 
determination of hydrogen bonds between 
aromatase with various ligands, default val-
ues of Gromacs were assigned. Based on 
default, r is the distance between heavy at-
om which is incorporated in generation of 
hydrogen bond in such a way that r ≤ 0.35 
nm. 3D-images of aromatase or its complex 
with docked ligands were rendered by 
UCSF Chimera (Goddard et al., 2005) or 
Pymol (Humphrey et al., 1996). 2D-images 
of aromatase-ligand interactions were cre-
ated by LigPlot (Laskowski and Swindells, 
2011).  
 
RESULTS AND DISCUSSION  
Internal validation phase 
Based on the free energy of binding of 
aromatase inhibitors, the more active and 
potent candidates were selected for further 
studies. So, its necessary to evaluate the 
accuracy of the calculated free energy of 
binding. For this purpose, eleven proven 
inhibitors were taken from the literature 
(Bonfield et al., 2012) and assigned as a test 
set. Table 1 shows the compound structures 
with their pIC50 and predicted free energy 
of binding (Bonfield et al., 2012). Figure 1 
shows the correlation between the experi-
mental IC50 and the estimated free energy 
of binding of test set which was calculated 
by Pearson correlation.  
 
 
 
 
Table 1: Compound structures, free energy of docking and the negative logarithm of IC50 of eleven 
aromatase inhibitors. This structures were taken from literature (Bonfield et al., 2012) 
O
OR5
R6
R7
R8
R2'
R3'
R4'
R5'
R6'
 
a pIC50: negative logarithm of Half maximal inhibitory concentration 
b ∆Gpredicted: predicted free energy of binding (kcal/mol)
Compound R5 R6 R7 R8 R2̒ R3̒ R4̒ R5̒ R6̒ pIC50a ∆Gpredictedb
1 H H H H H H H H H 4.53 -9.1 
2 H CH3 H H H H H H H 4.35 -9.2 
3 H H CH3 H H H H H H 4.74 -9.3 
4 H H H H H CH3 H H H 4.69 -8 
5 Benzo  H H H H H H H 4.69 -9.2 
6 H H H H H H PhO H H 5.61 -12.1 
7 H H H H CH3O H H H H 4.01 -6.5 
8 H H H H H CH3O H H H 4.00 -7.6 
9 H Cl H H H H H H H 5.29 -11.3 
10 H H H H 3 ̒- Pyridyl     5.23 -11.1 
11 H CH3O H H H H H H H 6.58 -13.3 
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Figure 1: Correlation between estimated free 
energy of binding of aromatase inhibitors calcu-
lated by Autodock vina and experimental activi-
ties(log IC50). R2 for this correlation was 0.88. 
 
 
The correlation between two variables 
reflects the degree to which the variables 
are related. The most common measure of 
correlation is the Pearson Product Moment 
Correlation (called Pearson's correlation for 
short). Pearson's correlation reflects the de-
gree of linear relationship between two var-
iables. It ranges from +1 to -1. A correla-
tion of +1 means that there is a perfect posi-
tive linear relationship between variables. 
Correlation value between experimental 
and theoretical data described as Pearson 
correlation coefficient or R2. The calculated 
R2 for this simulation was 0.88 which 
showed an acceptable correlation. This step 
is too important because the screening 
phase of this study is based on docking en-
ergy of each compound. It should be noted 
that the molecular docking study in valida-
tion phase was done against the intact crys-
tal structure of aromatase.  
 
Virtual screening through docking energy  
Among 286 compounds with structural 
similarity to 2a (Figure 2), which were 
docked against the minimized structure of 
aromatase, 150 compounds showed lower 
docking energy, compared with 2a. The 
docking energy for 2a was -8.5 kcal/mol, 
while 22 screened compounds had docking 
energies below -10 kcal/mol. The ASD as a 
natural substrate of aromatase by -13.8 had 
the lowest level of docking energy among 
all of docked compounds. Energy of dock-
ing for 21 compounds with 70 % of struc-
tural similarity to 2a, which had docking 
energy below -10 kcal/mol is indicated in 
Table 2 and their chemical structures are 
shown in Figure 3. 
 
Figure 2: Chemical structure of androstenedi-
one (ASD) as a natural substrate of Aromatase 
(A), 2a as an isoflavone derivative synthesized 
by Bonfield et al. (2012) with the most potent 
inhibitory effect (B), and 2a_1 with the lowest 
docking energy (-11.2 kcal/mol) against Aroma-
tase among 286 compounds with 70 % of struc-
tural similarity to 2a which were chosen for 
structure-based virtual screening (C). 
 
Figure 3: Among 286 chosen compounds from 
virtual screening which were docked against 
crystal structure of Aromatase, 22 of them had 
docking energies below -10 kcal/mol. The 
chemical structures of these compounds are 
depicted here. 2a_1 (Compound No. 1) by -11.2 
kcal/mol has the lowest docking energy. 
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Table 2: Among all of 286 docked compounds 
with 70 % of similarity to 2a which were cap-
tured from ZINC server, just 22 of them had 
docking energy equal to or lower than –10 
kcal/mol. These compounds are shown here.  
 
Compound ZINC ID Docking 
energy 
(kcal/mol) 
ASD  -13.8 
2a  -8.5 
2a_1 ZINC70389574 -11.2 
2a_2 ZINC04050552 -10.9 
2a_3 ZINC70389670 -10.8 
2a_4 ZINC70389688 -10.7 
2a_5 ZINC70389672 -10.5 
2a_6 ZINC38057582 -10.4 
2a_7 ZINC70389862 -10.4 
2a_8 ZINC04050553 -10.3 
2a_9 ZINC70389634 -10.3 
2a_10 ZINC70389712 -10.3 
2a_11 ZINC04050554 -10.2 
2a_12 ZINC37337218 -10.2 
2a_13 ZINC70389571 -10.2 
2a_14 ZINC70389581 -10.2 
2a_15 ZINC70389604 -10.2 
2a_16 ZINC70440058 -10.2 
2a_17 ZINC61617699 -10.1 
2a_18 ZINC70483805 -10.1 
2a_19 ZINC01391205 -10 
2a_20 ZINC38057583 -10 
2a_21 ZINC70389620 -10 
2a_22 ZINC70389687 -10 
 
 
On validation phase of docking process, 
ASD which is completely docked to aroma-
tase was imposed on ASD coordination in 
available crystal structure. RMSD of dock-
ing for ASD in comparison with its coordi-
nation in the crystal structure was zero. 
ASD in aromatase-ASD crystal structure is 
located near the heme group. This com-
pound interacts with Met374 just via one 
hydrogen bond which is generated through 
O2 (Figure 2), the oxygen atom attached to 
cyclohexane ring of ASD through double 
bond. Moreover, 2a and 2a_1 were located 
near ASD coordination in aromatase crystal 
structure through docking (Figure 4). Inter-
actions of ASD, 2a and 2a_1 with aroma-
tase were further investigated through 20 ns 
of MD simulation.  
 
 
Figure 4A 
 
Figure 4B 
Figure 4: Superimposition of ASD (blue), 2a 
(pink) and 2a_1 (red) within the active site of 
Aromatase (A) and their position relative to the 
heme group of Aromatase (B).  
 
 
Interaction of ASD with aromatase 
through 20 ns of MD simulation  
ASD is the natural substrate of aroma-
tase and has a high affinity for it, as can be 
seen from its docking energy. Root mean 
square deviation (RMSD) values for aroma-
tase as alone and in complex with ASD are 
different through 20 ns of MD simulation 
(Figure 5). Binding of ASD to aromatase 
after 6 ns could cause structural alternation, 
which could be seen from the distinct 
RMSD profiles. This different confor-
mation for aromatase in the presence of 
ASD was reported previously by Hong et 
al. (2007). They showed that proteolytic 
digestion of aromatase by the trypsin, with-
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out the substrate or in the presence of ASD, 
and even in the presence of reversible in-
hibitors results in various profiles of aroma-
tase fragments on SDS-PAGE (Hong et al., 
2007). ASD, through an extended network 
of hydrogen bonds (H-bonds) which re-
mains stable through 20 ns of MD simula-
tion, has a high affinity for active site of 
aromatase. The average number of hydro-
gen bonds between ASD and aromatase 
during the simulation time is 3.21 (Figure 
6). O1 of ASD makes a stable hydrogen 
bond with Thr310. Its O2 atom also inter-
acts with Met374 and Arg115 of aromatase 
through H-bonds (Figure 7). The role of 
Thr310 in aromatase active site as a partici-
pative residue was previously emphasized 
by site-directed mutagenesis (Chen and 
Zhou, 1992). T310S and T310C mutated 
types of aromatase just showed 48.8 % and 
2.4 % of wild-type Vmax, respectively (Chen 
and Zhou, 1992). The length of hydrogen 
bond generated between Thr310:HG1 and 
O1 of aromatase during 20 ns of MD simu-
lation is 2.301 Å. So, increase in H-bond 
length by replacement of threonine by ser-
ine with a shorter side chain, leads to the 
attenuation of H-bond and decreasing the 
Vmax of enzyme (Chen and Zhou, 1992). 
Replacement of Thr310 with a cysteine res-
idue, disrupts this H-bond and causes aro-
matase to become nearly inactive (Chen 
and Zhou, 1992). Root mean square fluc-
tuation (RMSF) of alpha carbons for 
Arg115 and Thr310 are also different be-
tween aromatase as free of substrate and in 
aromatase-ASD complex through 20 ns of 
MD simulation (Figure 8). 
 
 
Figure 5: Root mean square deviation of Aromatase (blue line), Aromatase-ASD complex (red line), 
Aromatase-2a complex (green line) and Aromatase-2a_1 complex (purple line) during 20 ns of molec-
ular dynamic simulation 
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Figure 6: Number of hydrogen bonds between ASD (blue line), 2a (red line) and 2a_1 (green line) 
with Aromatase through 20 ns of MD simulation 
 
 
       
 
Figure 7: (A) 2D-image of ASD and heme interactions with Aromatase after 20 ns of MD simulation. 
As indicated, the hydrogen bonds formed between O1 from ASD with Thr310 and O2 of ASD with 
Met374 and Arg115 are the major interactions which result in the high affinity of ASD for Aromatase. 
The numbers indicate the minimum distance between heavy atoms that are involved in generated hy-
drogen bonds. (B) 3D-image of ASD with Aromatase residues which have a key role in clamping of 
ASD by Aromatase through hydrogen bonds and their position in relation to the heme group.  
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Figure 8: Root mean square fluctuation of alpha carbons from Aromatase residues as alone (blue 
line) and in complex with ASD (red line). RMSF of alpha carbons from Arg115, Thr310 and Met374 
which interact with ASD via hydrogen bonds through 20 ns of MD simulation are indicated by the blue 
circle for Aromatase and by the red triangle for Aromatase-ASD complex.  
 
 
 
2a as isoflavanone derivative interacts 
with aromatase through hydrophobic in-
teractions  
2a as the most potent aromatase inhibi-
tor, which is synthesized by Bonfield et al. 
(2012), interacts with aromatase through 
hydrophobic interactions (Figure 9A). The 
average number of hydrogen bonds, which 
are formed between 2a and aromatase 
through 20 ns is 0.019 (Figure 6). Based on 
Figure 7A, it seems that hydrophobic inter-
actions are the most contributing forces in 
the stability of aromatase-2a complex. The 
hydrophobic pocket formed by residues like 
Ile133, Phe134, Ala306, Thr310, Leu372 
and Leu477 surrounds 2a. In fact, the 
RMSF values, which are reported here for 
alpha carbons of these residues through 20 
ns of MD simulation in the presence of 2a 
may arise from their hydrophobic interac-
tion with 2a (Figure 9B). The coordination 
of O2 of 2a with iron atom of aromatase 
heme group is so volatile. The average dis-
tance between O2 with Fe atom from the 
heme group is 0.632 nm, which seems too 
long to result in formation of a stable coor-
dination (Figure 10).  
 
Figure 9: (A) 2D-image of Aromatase-2a inter-
actions after 20 ns of MD simulation. 2a is sur-
rounded by a hydrophobic tunnel, which is 
made by Ile133, Phe134, Ala306, Thr310, 
Leu372, Val 373, Met374 and Leu477. 
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Figure 9: (B) The RMSF of alpha carbons of Aromatase (blue line) and Aromatase-2a residues (red 
line) through 20 ns MD simulation. Residues of Aromatase, which may interact with 2a through hydro-
phobic interactions are marked by blue circles. Same residues in Aromatase-2a complex are shown 
by red triangles. 
 
Figure 10: Distance between Iron atom from heme group of Aromatase with O2 of 2a (red line) and 
O2 of 2a_1 (blue line) through 20 ns of MD simulation. O2 from 2a_1 could coordinate in stable man-
ner with Fe atom from the Aromatase, while O2 of 2a coordination with iron atom is so weak and un-
stable. 
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Interaction of 2a_1 with aromatase via 
hydrophobic interactions and oxygen-iron 
coordination  
Although 2a_1 (3-[(2,3,5,6-tetramethyl-
phenyl)-carbonyl]-2,3-dihydro-1-benzofuran) 
does not interact with aromatase through 
hydrogen bonds (Figure 6), it extensively 
interacts with aromatase via hydrophobic 
interactions and furthermore makes a stable 
oxygen-iron coordination with the heme 
group of aromatase. 2a_1 is properly locat-
ed in the hydrophobic active site of aroma-
tase near its heme group. Tetra-
methylphenyl moiety of 2a_1 is clamped by 
the hydrophobic side chain of Trp224, 
Val373 and Met374 and its benzofuran 
moiety interacts with Phe134 from aroma-
tase (Figure 11A). The presence of 2a_1 in 
the active site of aromatase affects RMSD 
of its heme group through 20 ns of the sim-
ulation process (Figure 5). Average RMSD 
for heme group of the ligand-free aromatase 
is 0.136 nm, while in the presence of 2a_1 
the average RMSD of heme is 0.072 nm 
during 20 ns of MD simulation. 2a_1 inter-
acts with heme group of aromatase through 
its O2 atom which makes a stable coordina-
tion throughout the simulation time. In the 
ligand-free form of aromatase, six coordi-
nations of Fe atom from the heme group are 
occupied by four nitrogen atoms from heme 
group, a thiolate from Cys437 and an oxy-
gen atom from the water molecule which is 
used for aromatization of ASD. In the pres-
ence of 2a_1, Fe2+ atom of heme could 
make a stable coordination with O2 atom 
from 2a_1. At the beginning of the simula-
tion process, O2 atom of 2a_1 is located in 
the 0.43 nm of iron atom from heme group, 
but after just 0.2 ns of MD simulation it 
reaches to 0.15 nm of iron atom and re-
mains in that position during the remaining 
time of simulation. The average distance 
between O2 from 2a_1 and Fe atom is 
0.173 nm for 20 ns of MD simulation (Fig-
ure 10).  
 
 
Figure 11: (A) 2a_1 after 20 ns of MD simula-
tion surrounded by a hydrophobic hole which is 
made through Ile133, Phe134, Trp224, Ala306, 
Val373 and Met374 from Aromatase. (B) It 
seems that the high affinity of 2a_1 for Aroma-
tase is mediated not only via hydrophobic inter-
actions but also through a stable coordination, 
which forms between its O2 with Fe atom of 
heme group from Aromatase. This image 
shows the position of 2a_1 in relation to the 
heme group of Aromatase after 20 ns of simula-
tion process. 
 
CONCLUSION 
Phytoestrogens are a natural class of 
compounds, which are found in human die-
tary like grapes, soybean and berries (Ad-
lercreutz, 1995; Mazur et al., 2000; Kiely et 
al., 2003). Flavonoids subclasses like fla-
vanones, flavones and isoflavonoids and 
lignans compose two main groups of phy-
toestrogens (Karkola and Wahala, 2009; 
Milder et al., 2004). Size, shape and charg-
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es of some kinds of phytoestrogens are sim-
ilar to those of estrogen and so have a great 
potential to be used as aromatase inhibitors 
(Ibrahim and Abul-Hajj, 1990; Jeong et al., 
1999; Kellis and Vickery, 1984; Kao et al., 
1998). Role of these compounds in reduc-
ing occurrences of breast cancer has previ-
ously been emphasized (Adlercreutz, 1995). 
Many of the potent inhibitors of aromatase 
which are used today as efficient drugs, like 
letrozole or triazole make a stable coordina-
tion through their nitrogen atoms with iron 
atom of aromatase heme group (Miller et 
al., 2008; Hamilton and Volm, 2001). It 
seems that flavonoids not only could ac-
commodate in the hydrophobic active site 
of aromatase through their hydrophobic 
moieties, but they also could make a stable 
coordination with Fe atom of the heme 
group through their oxygen atom (Kellis 
and Vickery, 1984; Kellis et al., 1986, 
1987). Through procedures like microwave-
assisted, gold-catalyzed annulations of reac-
tion of hydroxyaldehyde and alkynes on A 
and B rings of isoflavanones, Bonfield and 
his coworkers made a series of compounds 
among which 2a (6-methoxy-3-phenyl-
chroman-4-one) is the most potent aroma-
tase inhibitor with the IC50 value of 0.26 
µM (Bonfield et al., 2012). In spite of all 
advantages of natural compounds like iso-
flavanone derivatives, their inhibitory effect 
on aromatase is so weak in comparison with 
available aromatase inhibitors like anastro-
zole with IC50 of 12 nM (Miller, 1999). In 
current study, chemical structure of 2a was 
used as a template for virtual screening 
through docking against available crystal 
structure of aromatase. Among 286 com-
pounds with 70% of structural similarity to 
2a, 3-[(2,3,5,6-tetramethylphenyl)carbonyl] 
-2,3-dihydro-1-benzofuran, which was 
named 2a_1, showed the highest affinity for 
aromatase. While the energy of docking for 
2a were -8.5 kcal/mol, docking energy for 
2a_1 was -11.2 kcal/mol. Interactions of 
2a_1 with aromatase was more investigated 
through 20 ns of MD simulation and com-
pared with ASD and 2a interactions. Hy-
drogen bonds are the main forces through 
which ASD interacts with aromatase. MD 
simulation studies showed that ASD exten-
sively interacts with aromatase via a stable 
network of hydrogen bonds with Met374, 
Arg115 and Thr310 throughout the time of 
simulation. 2a as the most important inhibi-
tor against aromatase which was synthe-
sized by Bonfield et al. (2012) just accom-
modates suitably in the hydrophobic active 
site of aromatase but could not coordinate 
with Fe atom of the heme group via its ox-
ygens. Role of the hydrophobic residues 
like Ala306, Thr310, Trp224, IIe133, 
Phe134, Val370, Leu372, Val373, Met374 
and Ser478 in the active site of aromatase 
has been previously proven (Yadav et al., 
2011). In fact, replacement of carbonyl 
groups with more hydrophilic groups in the 
aromatase inhibitors leads to destabilization 
of the enzyme-compound interaction, de-
creasing its inhibitory activity (Cepa et al., 
2008). In addition, another study has re-
ported that hydrophobic amino acids such 
as Ile132, Ile133, Ile305, Phe148, Met303, 
and Ala306 may play a critical role in the 
binding to the active site (Takahashi et al., 
2010). Our study demonstrated that 2a_1, 
which was selected through the virtual 
screening process, not only interacts suita-
bly with the hydrophobic active site of 
aromatase, but also it makes a stable coor-
dination with Fe atom of heme through an 
oxygen atom (O2). With such binding 
mechanism, this compound seems to be 
able to inhibit aromatase in the most effec-
tive way. Therefore, it may be proposed as 
the most potent inhibitor of aromatase and 
could be a new candidate for the treatment 
of breast cancer.  
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